<li>aliskiren<p>simvastatin will increase the level or effect of aliskiren by  P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.</p></li><li>alvimopan<p>simvastatin will increase the level or effect of alvimopan by  P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.</p></li><li>ambrisentan<p>simvastatin will increase the level or effect of ambrisentan by  P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.</p></li><li>armodafinil<p>simvastatin will increase the level or effect of armodafinil by  P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.</p></li><li>coenzyme q10<p>simvastatin decreases levels of coenzyme q10 by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>colestipol<p>colestipol decreases levels of simvastatin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>fexofenadine<p>simvastatin will increase the level or effect of fexofenadine by  P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.</p></li><li>fluvoxamine<p>fluvoxamine will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>isradipine<p>isradipine decreases levels of simvastatin by unknown mechanism. Minor/Significance Unknown.</p></li><li>loratadine<p>simvastatin will increase the level or effect of loratadine by  P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.</p></li><li>orlistat<p>orlistat increases effects of simvastatin by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>sacubitril/valsartan<p>sacubitril/valsartan increases toxicity of simvastatin by Other (see comment). Minor/Significance Unknown. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>telmisartan<p>telmisartan increases toxicity of simvastatin by Other (see comment). Minor/Significance Unknown. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>trazodone<p>trazodone increases levels of simvastatin by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>valsartan<p>valsartan increases toxicity of simvastatin by Other (see comment). Minor/Significance Unknown. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li>